FDA Nod for OTTAVA Robot Bolsters MedTech, But Core Risks Remain

What happened

Johnson & Johnson received FDA De Novo authorization for its OTTAVA robotic surgical system, the first table-integrated soft tissue robot, for multiple general surgery procedures. This approval strengthens JNJ's MedTech portfolio, which has been undergoing restructuring and potential orthopaedics separation. However, the company's near-term outlook remains dominated by STELARA biosimilar erosion and open-ended talc litigation liability, with the CVS formulary switch on July 1, 2026 as a key risk. The OTTAVA approval, while positive, does not alter the fundamental risk-reward asymmetry in the next 3-6 months, as immunology headwinds and legal uncertainties persist. The bull case for JNJ includes MedTech margin improvement and growth from new products, but current valuation at P/E 26.5 already prices in a smooth transition.

Implication

While the OTTAVA approval is a positive signal for JNJ's MedTech innovation and could support segment margin improvement as the Surgery restructuring progresses, it does not shift the near-term earnings trajectory meaningfully. Investors should wait for Q2-Q3 FY2026 results to confirm that immunology erosion from STELARA biosimilars is orderly and that TREMFYA and other growth drivers are offsetting declines. Talc litigation remains an unquantifiable overhang; any adverse legal ruling could reset downside risk, so position sizing should account for this. The OTTAVA authorization may contribute to a re-rating if MedTech growth accelerates, but the current risk/reward favors waiting for a better entry near $200 or after key catalysts clear. Therefore, maintain a WAIT stance, with a focus on the July 1 CVS formulary change and Q3 earnings for evidence of stabilization.

Thesis delta

The OTTAVA approval modestly strengthens the MedTech bull case but does not alter the central thesis that JNJ's near-term returns hinge on immunology erosion and talc litigation outcomes. The core risk-reward remains asymmetric to the downside until these catalysts play out.